TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00496548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin
Description: Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urinary PGE-M Level
Description: Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
Study: NCT01513486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: immobilization

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: immobilization
Study: NCT03994432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group
Description: follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model.
Study: NCT00312663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Falciparum Malaria Protein 11 with AS01B adjuvant.
Description: malaria experimental vaccine
Study: NCT02914028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane block
Description: A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol and paracetamol
Description: Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol and paracetamol
Description: Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
Study: NCT00708084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CL184
Description: CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRIG
Description: HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
Study: NCT00935090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Description: The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
Study: NCT02945891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens
Description: Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
Study: NCT03408119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried Plum
Description: Dried plum fruit, 100g or 50g depending on treatment group randomized to

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried Plum
Description: Dried plum fruit, 100g or 50g depending on treatment group randomized to

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D and 450mg elemental calcium
Description: Supplemental vitamin D and calcium to protect against further bone loss
Study: NCT02536404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03137667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-located Influenza Vaccination
Description: Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
Study: NCT03408119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D and 450mg elemental calcium
Description: Supplemental vitamin D and calcium to protect against further bone loss

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 800 IU vitamin D and 450mg elemental calcium
Description: Supplemental vitamin D and calcium to protect against further bone loss
Study: NCT02433431

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training
Description: Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Attention Only Training
Description: Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Analytic Thinking Training
Description: Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
Study: NCT03030742

Intervention type: OTHER
Intervention: Survey
Description: A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~* Satisfaction with pain control 2-4 weeks postpartum~* Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~* Patient characteristics associated with high opioid use~* Methods of storage and disposal of unused opioids

Intervention type: OTHER
Intervention: Survey
Description: A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~* Satisfaction with pain control 2-4 weeks postpartum~* Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~* Patient characteristics associated with high opioid use~* Methods of storage and disposal of unused opioids
Study: NCT02278523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT®
Description: A device used to offer threshold load to inspiratory muscle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold IMT®
Description: A device used to offer threshold load to inspiratory muscle
Study: NCT04821362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound group
Description: In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near Infrared Device Group
Description: In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
Study: NCT00289055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Cordis SMART™ Nitinol Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: balloon angioplasty
Study: NCT01629199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEGF(recombinant human Epidermal Growth Factor)
Study: NCT02616913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R,R-monatin
Description: Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
Study: NCT01564511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait trainer treatment
Description: Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
Study: NCT02616913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
Study: NCT01564511

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
Study: NCT00698230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 5 mg QD tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 15 mg QD tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 50 mg QD tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 100 mg QD tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 200 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator matching INCB013739
Description: Orally once daily tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT01638377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
Study: NCT02616913

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject consumes placebo in one of 3 treatment periods
Study: NCT02491385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic epidural analgesia
Description: In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv-PCA
Description: iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
Study: NCT02492945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3ml-Rejuvinex
Description: They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3ml-15%-dextrose solution
Description: They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
Study: NCT01247857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 30 mg
Description: Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 30 mg
Description: intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
Study: NCT02868203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Description: OCT after stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Description: OCT after stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eLuting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eLuting stent
Study: NCT01488253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
Study: NCT01902940

Intervention type: OTHER
Intervention: Natural History
Description: Assessment of natural history in IBM and CCFDN
Study: NCT04934930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Immunotherapy
Study: NCT02824484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GWDP
Description: In each writing session participants are asked to:~1. Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~2. Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~3. Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
Study: NCT03002974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Description: 100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Description: 100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40 mg
Description: 1 mL intramuscular injection of a 40 mg/mL injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Anakinra 100 mg
Description: sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Anakinra 100 mg
Description: sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Triamcinolone Acetonide 40 mg
Description: 1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Triamcinolone Acetonide 40 mg
Description: 1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
Study: NCT01580930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: 12 weeks, 5 days of week, 40 min per session of exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sedentary time reduction
Description: participants provided with strategies to decrease sitting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercsie training plus sedentary time reduction
Description: 12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
Study: NCT01629199

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of rhEGF(recombinant human Epidermal Growth Factor)
Study: NCT00610363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rilonacept)
Description: Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
Study: NCT01055899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN88
Description: Single SC Dose
Study: NCT02288884

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acticoat PostOp
Study: NCT02907476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Study: NCT02907476

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Study: NCT02929654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Verio®
Description: Colour Enhanced Blood Glucose Meter.
Study: NCT02288884

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OpSite PostOp
Study: NCT01814787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA Type 2 Diabetes Module
Description: Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI \> 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
Study: NCT02929654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Verio® Flex
Description: Colour Enhanced Blood Glucose Meter.
Study: NCT03251885

Intervention type: OTHER
Intervention: swabs
Description: Two swabs will be taken at each screen: one from the vagina and the other from the rectum for vaginal and rectal assessment of maternal colonization
Study: NCT03499847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardised face-to-face counselling session
Description: the healthcare provider will conduct a standardised face-to-face counselling session guided with subjects guided by a check-list of topics to cover regarding the Advanced Medical Directive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: advanced medical directive pamphlet
Description: A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
Study: NCT02929654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subject's Own Blood Glucose Meter
Description: Subject's Own Blood Glucose Meter
Study: NCT03156647

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of alpha-synuclein
Description: Test of levels of total and ratio total:oligomeric in saliva

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of alpha-synuclein
Description: Test of levels of total and ratio total:oligomeric in saliva

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of alpha-synuclein
Description: Test of levels of total and ratio total:oligomeric in saliva
Study: NCT01229462

Intervention type: DRUG
Group type: OTHER
Intervention: brimonidine tartrate/timolol fixed combination ophthalmic solution
Description: One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate ophthalmic solution
Description: One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol ophthalmic solution
Description: One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: fixed combination vehicle
Description: Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.